YXYong Xu

Yong Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yong Xu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Chao Gao

    Department of Urology, Second Hospital of Tianjin Medical University, Tianjin Institute of Urology Tianjin, China

    1 shared publication
  • Dashuai Zhu

    School of Medicine and

    1 shared publication
  • Deling Kong

    State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China

    1 shared publication
  • Guo-Wei Feng

    Department of Urology, Second Hospital of Tianjin Medical University, Tianjin Institute of Urology Tianjin, China

    1 shared publication
  • Guowei Feng

    School of Medicine and

    1 shared publication
  • Hongyan Tao

    School of Medicine and

    1 shared publication

Latest Publications

  • Open Access

    IGF-1 C Domain–Modified Hydrogel Enhances Cell Therapy for AKI

    by Guowei Feng, Jimin Zhang, Yang Li, Yan Nie, Dashuai Zhu, Ran Wang, Jianfeng Liu, Jie Gao, Na Liu, Ningning He, et al.

    Low cell retention and engraftment after transplantation limit the successful application of stem cell therapy for AKI. Engineered microenvironments consisting of a hydrogel matrix and growth factors have been increasingly successful in controlling stem cell fate by mimicking native stem cell niche components. Here, we synthesized a bioactive hydrogel by immobilizing the C domain peptide of IGF-1 (IGF-1C) on chitosan, and we hypothesized that this hydrogel could provide a favorable niche for adipose-derived mesenchymal stem cells (ADSCs) and thereby enhance cell survival in an AKI model. In vitro studies demonstrated that compared with no hydrogel or chitosan hydrogel only, the chitosan–IGF-1C hydrogel increased cell viability through paracrine effects. In vivo, cotransplantation of the chitosan–IGF-1C hydrogel and ADSCs in ischemic kidneys ameliorated renal function, likely by the observed promotion of stem cell survival and angiogenesis, as visualized by bioluminescence imaging and attenuation of fibrosis. In conclusion, IGF-1C immobilized on a chitosan hydrogel provides an artificial microenvironment for ADSCs and may be a promising therapeutic approach for AKI.


    • 15 March 2014
      • Vol. 7  (4) , 1764-70

    A young man with primary prostatic extra-gastrointestinal stromal tumor: a rare case report and review of the literature.

    by Zhi-Hong Zhang, Guo-Wei Feng, Zhi-Fei Liu, Lei Qiao, Tao Zhang, Chao Gao, Yong Xu

    Mounting evidence demonstrates the presence of extragastrointestinal stromal tumor (EGIST) which originates from tissues outside the gastrointestinal (GI) tract and shares overlapping immunohistological features with gastrointestinal stromal tumor (GIST). GIST emanating from prostate is extremely rare. To our knowledge, there are only 3 definitely reported cases of primary prostatic EGIST. Herein, we report a case of prostatic EGIST in 31-year-old man with low urinary tract symptoms who was initially misdiagnosed as sarcoma of prostate. Imaging studies assist in determining the origin and location of EGIST. Immunohistochemical assessment (DOG-1, CD117, and CD34) helps in differentiating such lesion from other stromal tumors and in addressing an appropriate and optimal therapeutic strategy.